RxDoctor Payments Data

Christine Shock, MD

Family Medicine · Indianapolis, INNPI 1528238441

Payments from drug & device makers

$1,623in general payments, 2019–2025

Across 117 payments — averaging $13.87 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Novo Nordisk$272
  • GSK$255
  • AbbVie$202
  • Takeda Pharmaceuticals U.S.A., Inc.$200
  • Merck$126
  • Amgen$124
  • plus $444 from 11 others

What the payments were for

  • Food & beverage$1,58598%
  • Education$382%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
23
24

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$1,623 in reported general payments places this provider in the 65th percentile of 2,709 family medicine providers in Indiana.

See all family medicine providers in Indiana

Medicare billing

Part B allowed, 2024
$69,040
Medicare patients
151
Services billed
737

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
JardianceEmpagliflozin28$42,577
Janumet XrSitagliptin Phos/Metformin Hcl12$19,230
MyrbetriqMirabegron17$15,984
VascepaIcosapent Ethyl18$14,061
SynthroidLevothyroxine Sodium49$5,012
Breo ElliptaFluticasone/Vilanterol11$4,358
Atorvastatin Calcium385$2,709
Omeprazole128$1,928
Rosuvastatin Calcium146$1,143
Pantoprazole Sodium73$1,060
Losartan Potassium105$1,017
Famotidine65$947
Gabapentin42$934
Levothyroxine Sodium151$873
Duloxetine Hcl52$860

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Boehringer IngelheimJardiance$35$42,57728 claims
MerckJanumet Xr$126$19,23012 claims
Astellas Pharma US IncMyrbetriq$33$15,98417 claims
AbbVieSynthroid$202$5,01249 claims
GSKBreo Ellipta$255$4,35811 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 65th percentile of 2,709 family medicine providers in Indiana.

Other family medicine in Indianapolis

See the full list for Indiana

Where these figures come from

Is this you, or does something look wrong? →